GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying high-stakes legal battles in the U.S.
Merck reported Q1 sales of $15.8 billion, beating estimates, with cancer drug Keytruda driving growth. Company raised full-year revenue and EPS forecasts.
Discover Bristol Myers Squibb's impressive first-quarter performance, with revenues exceeding expectations driven by key products like Eliquis and Reblozyl. Despite challenges, the company aims for significant cost savings and future growth.
Sanofi reports Q1 operating income at 2.8 billion euros, down 14.7%. Beat consensus EPS at $0.97. Sales reach $11.36 billion, led by Dupixent's 24.9% surge. Vaccine sales up 5.6%. Expecting Dupixent to hit €13 billion in 2024 sales. Blockbuster ambitions for Beyfortus.
AstraZeneca reports Q1 sales of $12.68 billion, up 17% Y/Y. Despite missing adjusted EPADS, oncology sees a 26% surge, driven by Tagrisso and Imfinzi. Cardiovascular sales up 20%. R&D up 18%. Fiscal 2024 outlook: low double-digit revenue and EPS growth.
Unlock the potential of adaptive immunity with ImmuneSelect by Virax Biolabs. Investigate T-Cell driven immunity for post-viral syndromes like Long COVID. Explore peptide pools and recombinant antibodies for immune profiling.
Explore the use of Amgen's Blincyto in treating severe systemic sclerosis, shedding light on Cullinan Therapeutics' CLN-978 potential for autoimmune diseases, particularly systemic lupus erythematosus.
Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and concerns about efficacy and costs hinder widespread adoption despite FDA approval.
Humana revises 2025 profit forecast due to disappointing Medicare Advantage reimbursement rates. Medical benefit ratio up to 88.9% in Q1 2024. Adjusted EPS growth outlook impacted by pricing decisions for 2025 MA bids.